List view / Grid view
29 February 2012 | By Novartis
Results of the COMFORT-I and COMFORT-II trials show INC424 significantly reduced disease burden in patients with myelofibrosis...
27 February 2012 | By Novartis
The European Commission has approved an update to the Glivec® (imatinib)* label...
17 February 2012 | By Novartis
CHMP concluded the risk-benefit review of Rasilez* (aliskiren)...
13 February 2012 | By Novartis
Novartis has received a Complete Response letter from the US FDA...
6 February 2012 | By Chamberlain Healthcare PR
The European Commission has approved the use of Galvus® (vildagliptin)...
1 February 2012 | By Novartis
The US Food and Drug Administration has approved an update to the Glivec® (imatinib)* label...
30 January 2012 | By Novartis
Novartis is a part of an international effort to eliminate or control 10 NTDs by the end of the decade...
20 January 2012 | By Novartis
Update of the Glivec® (imatinib)* label...
19 January 2012 | By Novartis
Sandoz announced that it has initiated two milestone Phase III clinical trials...
18 January 2012 | By Novartis
Novartis has received regulatory approval in China from the SFDA for Lucentis® (ranibizumab)...
13 January 2012 | By Novartis
US General Medicines restructuring results in reduction of 1,960 positions...
8 January 2012 | By Novartis
There have been no related adverse events reported with the issues leading to the recall...
15 December 2011 | By Novartis
Once-daily oral MS medicine showed a 48% relative reduction in annualized relapse rate, meeting primary endpoint in Phase III placebo-controlled study...
13 December 2011 | By Novartis
Results from two pivotal Phase III trials...
8 December 2011 | By Novartis
Updated results of a Phase III study...
